Skip to content
Research Article Open access CC BY 4.0

Antipsychotic Medications and Cognitive Behavior Therapy in Pregnant Women with Bipolar Disorder

Kimberly Morton Cuthrell, Milandeep Singh, Marly Villamar, Ushna Shabbir

Asian Journal of Biochemistry, Genetics and Molecular Biology · pp. 42–59 · Published 18 Oct 2022

10.9734/ajbgmb/2022/v12i4270

Abstract

One of the most difficult clinical tasks is treating pregnant women with bipolar disorder. Decisions that patients and physicians make are challenging, and no strategy is without risks nor prevents potential malpractice litigation. There is debate about whether to continue or discontinue antipsychotic medications during pregnancy. While discontinuation of antipsychotics may increase the risk of relapse, continued use of these medications may lead to fetal and maternal adverse outcomes. Some antipsychotics effectively treat symptoms related to bipolar disorder, including manic episodes and mood swings between mania and depression. Though antipsychotics may be useful for the treatment and management of bipolar disorder, the medications are not always favorable and are associated with adverse effects which have influenced some medical professionals to practice defensive medicine for decades that, in some cases, may coincide or conflict with medical ethics. While antipsychotics have a less safe yet effective impact on bipolar disorder in pregnant women, an alternative therapeutic approach such as Cognitive Behavior Therapy (CBT) should be considered. CBT psychotherapy is an evidence-based practice approach that can be beneficial in the treatment of bipolar disorder in pregnant women while bypassing the associated adverse reactions of antipsychotics. Attention is needed to explore the use and associated risks and benefits of antipsychotic medications during prenatal and postnatal, the debate of whether to continue or discontinue antipsychotic medication during pregnancy, and the role of CBT in the treatment of pregnant women with bipolar disorder. While antipsychotics may have beneficial effects that should not be underscored, the risks associated with the usage of antipsychotics during pregnancy cannot be minimized.

Bipolar disorder antipsychotic medication pregnant women cognitive behavior therapy defensive medicine medical ethics teratogenic

References (69)

  1. 1 Lifetime Prevalence and Age-of-Onset Distributions of DSM-IV Disorders in the National Comorbidity Survey Replication [DOI]
  2. 2 Prevalence and Correlates of Bipolar Spectrum Disorder in the World Mental Health Survey Initiative [DOI]
  3. 3 The Long-term Natural History of the Weekly Symptomatic Status of Bipolar I Disorder [DOI]
  4. 4 The American Journal of Obstetrics and Gynecology 1920–1945 [DOI]
  5. 5 The Journal of Neuropsychiatry and Clinical Neurosciences [DOI]
  6. 6 Psychiatric Disorders in Pregnant and Postpartum Women in the United States [DOI]
  7. 7 Cognitive Impairment and Functional Outcome in Schizophrenia and Bipolar Disorder [DOI]
  8. 8 Prevalence of suicidality during pregnancy and the postpartum [DOI]
  9. 9 Bipolar disorder, affective psychosis, and schizophrenia in pregnancy and the post-partum period [DOI]
  10. 10 Sleep and Circadian Rhythms in Bipolar Disorder: Seeking Synchrony, Harmony, and Regulation [DOI]
  11. 11 Risk of Recurrence of Bipolar Disorder in Pregnant and Nonpregnant Women After Discontinuing Lithium Maintenance [DOI]
  12. 12 The Stanley Foundation Bipolar Treatment Outcome Network [DOI]
  13. 13 Functioning and Disability in Bipolar Disorder: An Extensive Review [DOI]
  14. 14 Management of Bipolar Disorder During Pregnancy and the Postpartum Period [DOI]
  15. 15 Congenital malformations due to antiepileptic drugs [DOI]
  16. 16 Epidemiology of suicide in bipolar disorders: a systematic review of the literature [DOI]
  17. 17 Adjunctive Psychotherapy for Bipolar Disorder: State of the Evidence [DOI]
  18. 18 A review of empirically supported psychological therapies for mood disorders in adults [DOI]
  19. 19 Antipsychotic Therapy During Early and Late Pregnancy. A Systematic Review [DOI]
  20. 20 An estimate of the minimum economic burden of bipolar I and II disorders in the United States: 2009 [DOI]
  21. 21 Major malformations in offspring of women with epilepsy [DOI]
  22. 22 Evidence-Based Practice: The Psychology of EBP Implementation [DOI]
  23. 23 Fetal antiepileptic drug exposure: Adaptive and emotional/behavioral functioning at age 6years [DOI]
  24. 24 Birth weight of infants after maternal exposure to typical and atypical antipsychotics: Prospective comparison study [DOI]
  25. 25 Substance use disorders among adolescents with bipolar spectrum disorders [DOI]
  26. 26 Defensive medicine: A bane to healthcare [DOI]
  27. 27 Prenatal Antipsychotic Exposure and Neuromotor Performance During Infancy [DOI]
  28. 28 Cognitive Therapy for Bipolar Illness—A Pilot Study of Relapse Prevention [DOI]
  29. 29 Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score [DOI]
  30. 30 Psychoeducation and cognitive‐behavioral therapy in bipolar disorder: an update [DOI]
  31. 31 Perinatal outcomes among women with bipolar disorder: a population-based cohort study [DOI]
  32. 32 The societal cost of bipolar disorder in Sweden [DOI]
  33. 33 The promise of cognitive behavior therapy for treatment of severe mental disorders: a review of recent developments [DOI]
  34. 34 Possible teratogenic effect of phenothiazines in human beings [DOI]
  35. 35 Healthy Outcome under Olanzapine Treatment in a Pregnant Woman [DOI]
  36. 36 Use of Atypical Antipsychotics During Pregnancy and the Risk of Neural Tube Defects in Infants [DOI]
  37. 37 Lithium treatment during pregnancy, delivery, and lactation: an update.
  38. 38 Antipsychotics During Pregnancy [DOI]
  39. 39 Sexual health and women with bipolar disorder [DOI]
  40. 40 Possible Delayed Speech Acquisition With Clozapine Therapy During Pregnancy and Lactation [DOI]
  41. 41 The potential risks of commonly prescribed antipsychotics: during pregnancy and lactation.
  42. 42 Cognitive-Behavioral Therapy for Depression in Bipolar Disorder: A Meta-Analysis [DOI]
  43. 43 Polycystic ovary syndrome [DOI]
  44. 44 Psychosocial Interventions as Adjunctive Therapy for Bipolar Disorder [DOI]
  45. 45 Fetal Damage Due to ECT, Insulin Coma, Chlorpromazine, or Reserpine [DOI]
  46. 46 Safety Evaluation of Haloperidol in the Treatment of Hyperemesis Gravidarum [DOI]
  47. 47 Haloperidol overdose during pregnancy [DOI]
  48. 48 Placental transfer of chlorpromazine. Case report. [DOI]
  49. 49 Olanzapine and pregnancy.
  50. 50 Drugs in Pregnancy and Lactation. A Reference Guide to Fetal and Neonatal Risk. [DOI]
  51. 51 Prevalence, Severity, and Comorbidity of 12-Month DSM-IV Disorders in the National Comorbidity Survey Replication [DOI]
  52. 52 Pharmacological treatment of adult bipolar disorder [DOI]
  53. 53 Evidence-Based Psychotherapy: Advantages and Challenges [DOI]
  54. 54 Efficacy of cognitive-behavioral therapy in patients with bipolar disorder: A meta-analysis of randomized controlled trials [DOI]
  55. 55 Abrupt Discontinuation of Psychotropic Drugs Following Confirmation of Pregnancy: A Risky Practice [DOI]
  56. 56 A review of the safety of clozapine during pregnancy and lactation [DOI]
  57. 57 Resistance is not futile: treatment-refractory schizophrenia – overview, evaluation and treatment [DOI]
  58. 58 Current Treatment Options in Psychiatry [DOI]
  59. 59 Use of Antipsychotic Drugs During Pregnancy [DOI]
  60. 60 Bipolar disorder in women [DOI]
  61. 61 Antidepressant and antipsychotic prescribing in primary care for people with dementia.
  62. 62 Psychosocial Treatments for Bipolar Depression: A 1-Year Randomized Trial From the Systematic Treatment Enhancement Program [DOI]
  63. 63 Effect of Individual Counseling Program by a Midwife on Anxiety during Pregnancy in Nulliparous Women [DOI]
  64. 64 Development of a tool for monitoring the prescribing of antipsychotic medications to people with dementia in general practice: a modified eDelphi consensus study [DOI]
  65. 65 Withdrawal emergent syndrome in an infant associated with maternal haloperidol therapy.
  66. 66 Risperidone (Risperdal) [DOI]
  67. 67 Annals of Medical and Health Sciences Research [DOI]
  68. 68 Asian Journal of Advances in Medical Science [DOI]
  69. 69 Cognitive Behavior Therapy [DOI]

Cited by 2

Nutritional Psychiatry Integrated Framework: Exploration of Nutrition and Co-occurring Bipolar Disorder and Post-traumatic Stress Disorder

Kimberly Morton Cuthrell · International Neuropsychiatric Disease Journal · 2022

Showing 1 of 2 known citations — external sources report more than can currently be individually listed.

Related research

Article metrics

Real usage data collected on this platform.

71

Page views

0

PDF downloads

39

Outbound clicks

2

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.